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The impact of vaccination on the breadth and
magnitude of the antibody response to influenza
A viruses in HIV-infected individuals
Ines Kohlera,c, Roger Kouyosa,b, Matteo Bianchia, Christina Grubeb,
Arkadiusz Wyrzuckia,c, Huldrych F. Gu¨ntharda,b and
Lars Hangartnera,c
Objective: HIV-positive individuals have lower antibody titers to influenza viruses than
HIV-negative individuals, and the benefits of the annual vaccinations are controver-
sially discussed. Also, there is no information about the breadth of the antibody response
in HIV-infected individuals.
Design: The binding and neutralizing antibody titers to various human and nonhuman
influenza A virus strainwere determined in sera from 146HIV-infected volunteers: They
were compared with those found in 305 randomly selected HIV-negative donors, and
put in relation to HIV-specific parameters. Univariable and multivariable regression
was used to identify HIV-specific parameters associated with the measured binding and
neutralizing activity.
Methods: Enzyme-linked immunosorbent assays and in-vitro neutralization assays
were used to determine the binding and neutralizing antibodiy titers to homo and
heterosubtypic influenza A subtypes.
Results: We found that both homo and heterosubtypic antibody titers are lower in HIV-
positive individuals. Vaccination promoted higher binding and neutralizing antibody
titers to human but not to nonhuman isolates. HIV-induced immune damage (high viral
load, low CD4þ T-cell counts, and long untreated disease progression) is associated
with impaired homosubtypic responses, but can have beneficial effects on the devel-
opment of heterosubtypic antibodies, and an improved ratio of binding to neutralizing
antibody titers to homosubtypic isolates.
Conclusions: Our results indicate that repetitive vaccinations in HIV-positive individ-
uals enhance antibody titers to human isolates. Interestingly, development of antibody
titers to conserved heterosubtypic epitopes paradoxically appeared to profit from HIV-
induced immune damage, as did the ratio of binding to neutralizing antibodies.
Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
HIV-infected individuals have increased morbidity and
mortality following influenza virus infection [1]. Current
influenza virus vaccines are formulated as trivalent
inoculum (TIV) and rely on inducing highly strain-
specific neutralizing antibodies. Therefore, they need
to be revised, reformulated, and re-applied annually. A
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pan-influenza vaccine based on strain-insensitive hetero-
subtypic antibodies would be desirable. It is suspected that
some influenza vaccines, such as the H1/pdm09 vaccine,
promote production of cross-reactive antibodies, whereas
original antigenic sin (OAS), that is the preferential
expansionofmemoryBcell clones from the initial immune
response [2–4], most likely restricts their generation. We
could recently show that repetitive vaccination of HIV-
negative individuals generally stimulates homo and
heterosubtypic responses [5].
The effectiveness of currently available influenza vaccines
in HIV-positive individuals is controversially discussed.
Meta-analyses estimated the effectiveness of the non-
adjuvanted influenza virus vaccines in HIV-infected
individuals to be only 27–78% [6], even with increased
antigen dose and booster administration [7]. Nonetheless,
HIV-infected children and adolescents have a significant
increase in antibodies to the influenza virus strains
following vaccination. Influenza virus-specific antibody
titers, however, are significantly lower in HIV-positive
than in HIV-negative individuals [8].
Factors contributing to the modest antibody response to
TIV include both damage to the CD4þ T-cell compart-
ment and HIV-mediated alterations in the B-cell
compartment. These include the impaired generation
and reactivation of antigen-specific memory B cells [9],
and the shrinking of the memory B cell compartment
[10]. Antiretroviral therapy (ART) stops HIV disease
progression, but the extent of recovery of the naı¨ve and
resting B cell compartment depends on the stage at which
ARTwas started [11]. We therefore investigated to which
degree the response to TIV depends on HIV disease-
related parameters such as viral RNA load, CD4þ T-cell
counts, the duration of untreated HIV disease pro-
gression, and CD4þ T-cell nadir, and whether repetitive
vaccination helps to restore or maintain antibody titers to
influenza A viruses in HIV-infected individuals.
Methods
Ethics statement and participant recruitment
All HIV-1 infected individuals enrolled in this study were
cared for at the Division of Infectious Diseases and
Hospital Epidemiology, University Hospital Zurich and
are participating in the Swiss HIV Cohort Study [12],
and/or the Zurich Primary HIV Infection Study (ZPHI)
[13,14]. The protocol for this study has been reviewed
and approved by the ethics committee of the University
Hospital Zurich and written informed consent was
obtained from all participants. The Swiss HIV cohort
study was approved by individual local institutional
review boards of all participating centers and written
informed consent was also approved for the SHCS. The
ZPHI Study is approved by the local ethics board and
written informed consent was obtained.
The majority of non-HIV-infected study participants
have randomly been recruited from the members of the
University and the University Hospital of Zurich,
Switzerland. All participants completed a questionnaire
to assess their influenza exposure history. After informed
consent was obtained, a blood sample was drawn.
Enrollment ran for the most part from 20 October,
2009 to 30 October, 2009, before the onset of the Swine
Flu pandemic. Where available, data were completed
with HIV-specific parameters provided by the SHCS.
Our cohort comprised 83%males with a median value for
age of 44 [interquartile range (IQR) 38–50], for
vaccinations of 5 (IQR 2–9) and for the number of
perceived influenza episodes of two (IQR 0–4).
Details on experimental and statistical methods can be
found in the supplementary methods section, http://
links.lww.com/QAD/A732. A comprehensive analysis of
the non-HIV-infected cohort has already been published
elsewhere [5].
Results
To investigate the impact of influenza vaccination and
HIV-disease parameters on the breadth and magnitude of
hetero and homosubtypic antibody responses in HIV-
infected individuals, we collected serum from 146
randomly selected HIV-positive volunteers [most of
which are also participating in the Swiss HIV Cohort
Study (SHCS)] in October 2009. Using recombinant
hemagglutinin (HA) proteins (c.f. supplementary
methods, http://links.lww.com/QAD/A732), binding
antibody titers to five human and three nonhuman
influenza isolates were determined. Moreover, neutraliz-
ing antibody titers to five human and four avian influenza
isolates were also measured (Fig. 1). At a serum dilution of
1 in 30, more than half of all HIV-infected donors were
found to possess heterosubtypic antibodies (Fig. 1). These
were then compared with epidemiological baseline
characteristics, such as the number of vaccinations, the
age, HIV status, and HIV-specific parameters (CD4þ
T-cell counts, viral load, time period before and since
ART), and put in relation with data from a previous study
that analyzed sera from 305 HIV-negative individuals [5].
Impact of an HIV-infection on the breadth and
magnitude of the humoral antibody response to
influenza A virus
As depicted in Fig. 2 and supplementary Tables S1 and S2
(http://links.lww.com/QAD/A732), HIV-infected indi-
viduals displayed lower binding titers than HIV-negative
donors. In univariable analyses, binding titers to
homosubtypic rH1/34 and rH3/99 viruses were lower
in HIV-positive individuals compared with HIV-negative
individuals. In contrast, neutralizing titers did not seem to
differ between seronegative and seropositive individuals,
except for H1/34 wherein higher neutralizing titers were
1804 AIDS 2015, Vol 29 No 14
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found in HIV-positive donors. Correcting for the
number of vaccinations, age and sex did not change
the significance of this observation (Fig. 2; supplementary
Table S3, http://links.lww.com/QAD/A732). Binding
titers to H7N7 virions directly coated to plates and
neutralizing titers to H1/34, H3/07, H2/57, and H4/56
were comparable with those of HIV-negative donors.
Neutralizing titers to H5 and H7 were too small to be
fitted accurately into the Hill-equation. A surrogate value
corresponding to the percentage neutralization at a serum
dilution of 1 in 90 was used for the analyses. Albeit more
extensive scattering, these values were also comparable
between HIV-positive and HIV-negative donors.
These data indicate that an HIV infection has a more
pronounced negative impact on the binding than on the
neutralizing titers to human isolates; however, this
difference was clearly less pronounced for H3 isolates.
The neutralizing titers appeared to be less affected than
the binding titers, suggesting that in HIV-infected
individuals, the antibody response is more focused on
neutralizing epitopes. This hypothesis is also supported
by statistical examination of the fraction between the
binding and the neutralizing antibody titers (supple-
mentary Table S4, http://links.lww.com/QAD/A732)
showing a better neutralizing to binding antibody titer
ratio in HIV-infected individuals for most tested strains
even after adjusting for the number of vaccinations.
Impact of HIV-related parameters on the breadth
and magnitude of the humoral antibody response
to influenza A virus
The impact of HIV-induced damage to the immune
system was further evaluated using the following
parameters: the last CD4þ counts before the onset of
ART (LCD4), the state of the CD4þ compartment before
the study (ICD4), the CD4þ nadir (Table 1), the mean
RNA levels during the year before the study (Table 2), the
number of ambiguous nucleotide calls – a measure for
HIV-diversity and marker for duration of infection
(AMB) [15], and the duration of untreated disease
progression (UTDP) following infection as measured by a
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Fig. 1. Prevalence and distribution of homosubtypic and heterosubtypic serum antibodies in HIV-1-infected individuals. (a)
Serum antibody reactivities against the indicated immobilized recombinant hemagglutinin were assessed by ELISA. Values are
shown as the logarithm of the reciprocal serum dilution giving a half-maximal signal (log EC50). (b) Percentage of participants
displaying ELISA signals that are greater than the half-maximal value against the indicatedHA subtype at a serum dilution of 1 in 30
and 1 in 90. (c) Half-maximal inhibitory serum antibody titer (log IC50) to human and avian virus isolates. Values are shown as
logarithm of the reciprocal serum dilution. (d) Inhibition percentage against H5/04 and H7/79 at a serum dilution of 1 in 90.
Nonlinear regression could not be performed, as neutralizing titers were too low for these two subtypes. Neutralization was tested
against the indicated viruses at amultiplicity of infection of 2–6 (c) and (d). Boxplots are indicatingmedian and interquartile ranges
(IQRs). Whiskers include lower or upper quartile þ1.5 IQR.
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CD4þ-based statistical method developed by Taffe et al.
[16] (UTDP; Table 3; complete analyses in supple-
mentary Table S5, http://links.lww.com/QAD/A732).
The state of the CD4þ compartment at the last
measurement before the blood draw (ICD4) had no
significant influence on the binding and neutralizing
1806 AIDS 2015, Vol 29 No 14
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Fig. 2. Linear regression models comparing influenza titers of HIV-positive and HIV-negative populations. Univariable (solid
squares) and multivariable (open squares) linear regression models comparing (a) binding and neutralizing titers to influenza
homosubtypes (b) binding and neutralizing titers to heterosubtypes of HIV-negative individuals to HIV-positive individuals. Values
are indicating regression coefficients; 95% confidence intervals are indicated. The same ELISA and neutralizing data as in Figure 1
were used for this analysis. A value of zero represents equal antibody titers of HIV-1 negative and HIV-1 positive individuals,
positive values favor HIV-positive and negative ones HIV-negative individuals.
Table 1. Univariable and multivariable linear regressions analyzing binding titers (logEC50) and neutralizing titers (logIC50) in relation with
CD4R cell counts and other characteristics.
rHA Characteristics Regression coefficient (95% CI) P
rH1/34 Univariable LCD4 0.77 (0.10 to 1.44) 0.025
Multivariable LCD4 0.82 (0.16 to –1.49) 0.015
Number of vaccinations 0.037 (0.0037 to 0.070) 0.030
rH1/34 Univariable ICD4 0.66 (0.71 to –1.25) 0.028
Multivariable ICD4 0.57 (–0.025 to –1.17) 0.060
Number of vaccinations 0.032 (–0.0016 to 0.065) 0.062
rH1pdm/09 Univariable ICD4 –0.27 (–0.51 to –0.019) 0.035
Multivariable ICD4 –0.27 (–0.51 to –0.037) 0.024
Number of vaccinations –0.0055 (–0.019 to 0.0077) 0.410
rH5/04 Univariable ICD4 –0.36 (–0.70 to –0.033) 0.031
Multivariable ICD4 –0.38 (–0.72 to –0.051) 0.024
Number of vaccinations 0.00056 (–0.018 to 0.019) 0.952
rH1/34 Univariable Nadir 1.04 (–0.026 to 2.11) 0.056
Multivariable Nadir 1.44 (0.36 to 2.51) 0.010
Number of vaccinations 0.041 (0.0075 to 0.074) 0.017
Virus Characteristics Regression coefficient (95% CI) P
H5/04 Univariable ICD4 –11.34 (–19.94 to –2.73) 0.010
Multivariable ICD4 –11.45 (–20.38 to –2.52) 0.012
Number of vaccinations 0.11 (–0.39 to 0.61) 0.662
H2/57 Univariable Nadir –0.67 (–1.23 to –0.11) 0.019
Multivariable Nadir –0.38 (–0.84 to 0.092) 0.114
Number of vaccinations 0.10 (–0.0039 to 0.025) 0.151
ICD4, CD4þ cell count before onset of influenza study; LCD4, last CD4þ cell count before onset of ART; rHAs, recombinant hemagglutinin. CD4þ
cell numbers are indicated per 1000. Bold values and characteristics indicate P<0.05. Regressions were additionally adjusted for age and sex.
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antibody titers. Only neutralizing titers to H5/04 were
found to decrease with lower CD4þ T-cell counts. Yet,
this observation partially may be an artifact because of the
larger scattering of the surrogate values.
The number of CD4þ cells before the initiation of ART
(LCD4) did not have a major impact on binding or
neutralizing antibody titers with the exception of the
binding titers to H1/34 isolate, which were additionally
influenced by the number of vaccinations. Similarly, the
CD4þ nadir also did not have a significant effect on
antibody titers with the exception of binding titers to
homosubtypic rH1/34, where correcting for the number
of vaccinations showed an effect on both. The mean HIV
Influenza antibodies in HIV-infected individuals Kohler et al. 1807
Table 2. Univariable and multivariable linear regressions analyzing binding titers (logEC50) and neutralizing titers (logIC50) in relation with HIV
viral loads.
rHA Characteristics Regression coefficient (95% CI) P
rH7vir/79 Univariable Mean RNA 0.050 (0.018 to 0.082) 0.003
Multivariable Mean RNA 0.058 (0.024 to 0.091) 0.001
Number of vaccinations 0.0016 (–0.0097 to 0.013) 0.775
Virus Characteristics Regression coefficient (95% CI) P
H2/57 Univariable Mean RNA –0.093 (–0.14 to –0.042) <0.001
Multivariable Mean RNA –0.055 (–0.098 to –0.012) 0.013
Number of vaccinations 0.0095 (–0.0050 to 0.024) 0.198
H3/07 Univariable Mean RNA –0.18 (–0.30 to –0.060) 0.003
Multivariable Mean RNA –0.16 (–0.29 to –0.038) 0.011
Number of vaccinations 0.0029 (–0.039 to 0.045) 0.890
H3/68 Univariable Mean RNA –0.10 (–0.17 to –0.034) 0.003
Multivariable Mean RNA –0.058 (–0.11 to –0.0020) 0.043
Number of vaccinations 0.0050 (–0.014 to 0.024) 0.597
H5/04 Univariable Mean RNA 1.52 (0.12 to 2.92) 0.033
Multivariable Mean RNA 1.70 (0.23 to 3.17) 0.024
Number of vaccinations 0.24 (–0.26 to 0.74) 0.342
RNA values are noted as log values (logRNA copies/ml). rHAs, recombinant hemagglutinin. Bold values and characteristics indicate P<0.05.
Multivariable regressions were additionally adjusted for age and sex.
Table 3. Univariable and multivariable linear regressions analyzing binding titers (logEC50) and neutralizing titers (logIC50) in relation with
temporal parameters and other characteristics.
rHA Characteristics Regression coefficient (95% CI) P
rH1/34 Univariable AMB –17.0048 (–31.11 to –2.90) 0.019
Multivariable AMB –16.89 (–31.27 to –2.51) 0.022
Number of vaccinations 0.047 (0.0038 to 0.091) 0.034
rH1/34 Univariable ARTD 0.031 (0.0024 to 0.060) 0.034
Multivariable ARTD 0.011 (–0.026 to 0.049) 0.543
Number of vaccinations 0.030 (–0.011 to 0.070) 0.155
rH3/99 Univariable ARTD 0.029 (0.10 to 0.047) 0.002
Multivariable ARTD 0.029 (0.0062 to 0.052) 0.013
Number of vaccinations 0.011 (–0.014 to 0.036) 0.376
Virus Characteristics Regression coefficient (95% CI) P
H1/07 Univariable ARTD 0.029 (0.0040 to 0.054) 0.023
Multivariable ARTD 0.016 (–0.016 to 0.048) 0.326
Number of vaccinations 0.010 (–0.024 to 0.045) 0.547
H3/68 Univariable ARTD 0.029 (0.010 to 0.048) 0.003
Multivariable ARTD 0.0048 (–0.016 to 0.025) 0.641
Number of vaccinations 0.0059 (–0.016 to 0.028) 0.594
H2/57 Univariable ARTD 0.028 (0.013 to 0.042) <0.001
Multivariable ARTD 0.0053 (–0.10 to 0.021) 0.508
Number of vaccinations 0.010 (–0.0069 to 0.027) 0.204
H2/57 Univariable UTDP 0.026 (0.0074 to 0.045) 0.007
Multivariable UTDP 0.0023 (–0.015 to 0.020) 0.790
Number of vaccinations 0.012 (–0.0039 to 0.027) 0.140
H5/04 Univariable UTDP 0.61 (0.10 to 1.11) 0.019
Multivariable UTDP 0.61 (0.041 to 1.19) 0.036
Number of vaccinations –0.11 (–0.63 to 0.41) 0.680
AMB, fraction of ambiguous nucleotides; ARTD, time since onset of ART till onset of influenza study (year1); rHAs, recombinant hemagglutinin;
UTDP, untreated duration of disease progression (year1). Bold values and characteristics indicate P<0.05. Regressionswere additionally adjusted
for age and sex.
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RNA levels in the year before the blood sampling did
have a negative impact on homosubtypic titers to H3/07,
and to some extent also to H3/68 (Table 2). Moreover,
binding titers to rH2/57 were also decreased when higher
RNA levels were present, but this observation was
confounded by age (supplementary Table S5, http://
links.lww.com/QAD/A732). In contrast, high mean
RNA levels correlated with increasing neutralizing
activity to H5/04 at a 1 in 90 serum dilution. Similar
findings were made with binding titers to purified H7
virions directly coated on plates: higher mean HIV RNA
levels appeared to favor also development of more binding
antibodies to avian H7. However, this improvement was
also affected by being born before 1957.
The number of ambiguous nucleotide calls (AMB) [15], a
marker for duration of the infection, negatively correlated
with binding titers to rH1/34 (Table 3). A prolonged
duration of untreated disease progression (UTDP) had a
positive impact on the development of neutralizing titers
to H5/04 but on no other titers. The duration of ART
treatment (ARTD) only had a positive effect on binding
antibodies to rH3/99, even after correcting for vaccina-
tion and age (Table 3).
Thus, in summary, there was no HIV-related parameter
that could be used as a reliable predictor for the breath or
magnitude of the humoral response to influenza Aviruses.
Quite interestingly though is the observation that in cases
wherein an impact of the HIV-induced damage to the
immune system was detected, it tended to be negative for
human, but positive for avian nonhuman isolates.
Impact of influenza vaccination in HIV-infected
individuals
Next, when the impact of vaccination on homo- and
heterosubtypicantibodytiterswasanalyzed(supplementary
Table S6, http://links.lww.com/QAD/A732), it became
apparent that the number of vaccinations yielded no
significant improvement in neutralizing titers to the strains
included in the last vaccine applied before the blood
donation (i.e., H1/09 and H3/07). Yet, the number of
vaccinations clearly improved binding and neutralizing
titers to theolder influenzavirus isolatesH1/34andH3/68.
For latter, being born before 1957 was found to be a
confounding factor in the multivariate analysis (supple-
mentary Table S6, http://links.lww.com/QAD/A732).
This is probably because of an epitope shared between
rH1pdm/09 and H1N1 viruses circulating before 1957
[17].
With respect to heterosubtypic responses, vaccination or
age had no impact on either binding or neutralizing titers.
Binding and neutralizing titers to H2/57 were signifi-
cantly better in individuals born before 1968, thus those
who actually could have been infected with this subtype.
It was therefore not surprising to find confounding of age
for all H2/57-specific antibody titers. When adjusting the
impact of vaccination on heterosubtypic binding titers by
age (supplementary Table S6, http://links.lww.com/
QAD/A732), we additionally found that in participants
born between 1928 and 1957, binding titers to rH1pdm/
09 were also positively associated with increasing age.
It can therefore be deducted that although the response to
recently applied strains was moderate, vaccination helped
to maintain titers to older isolates. It was therefore
partially able to undo/prevent deterioration of these titers
following HIV infection.
Discussion
For the first time, in addition to human influenza A
viruses, we also included avian influenza A viruses and
assessed the impact of an HIV-infection on binding and
neutralizing antibody titers. We could show that all HIV-
positive donors bore homosubtypic and half of them also
heterosubtypic serum antibodies, albeit at lower titers
than HIV-negative donors. Vaccination increased homo-
subtypic but had no impact on heterosubtypic antibody
titers, which is in contrast to HIV-negative donors. Viral
load, CD4þ T-cell counts, and antiviral treatment were
found as predictors for some binding and neutralizing
antibodies to both human and nonhuman subtypes.
The generally lower binding titers found in HIV-positive
donors against humans and avian viruses compare well to
observations made in other studies investigating pre-
vaccination sera [18], and probably are the result of the
poorer vaccine response in HIV-positive individuals [8].
However, using inverted H7-proteins in ELISA, we
could demonstrate that also in HIV-positive donors, most
of the heterosubtypic antibodies recognized conserved
eptiopes in the stem of the HA protein (supplementary
Figure S1, http://links.lww.com/QAD/A732).
As the memory B cell compartment remains comprom-
ised under ART [19], we hypothesized that the antibody
response to influenza vaccination would be less affected
by OAS-related limitations. However, this was not the
case, as we found stronger binding and neutralizing
antibody responses to older than to more recent strains in
frequently vaccinated HIV-positive individuals. Thus,
HIV-induced damage to the immune system clearly
impairs the vaccine response to homosubtypic viruses.
In contrast to binding titers, only small differences in
neutralizing titers betweenHIV-positive andHIV-negative
individuals were found. More frequent vaccination of the
HIV-positive group is likely to account for these minor
differences. Interestingly, however, was the finding that the
difference between binding and neutralizing titers (log
EC50 – log IC50) was much lower in HIV-infected
(supplementary Table S4, http://links.lww.com/QAD/
1808 AIDS 2015, Vol 29 No 14
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A732) when compared with HIV-negative individuals.
This was most prominent for the old H1/34 isolate
wherein HIV-infected individuals clearly produced less
non-neutralizing, HA-binding antibodies than uninfected
donors, but showed similar titers of neutralizing antibodies.
One may speculate that the immune damage induced by
HIV preferentially depleted the immune system of B cells
with biologically irrelevant antibody specificities, which
would normally compete with more specific and
biologically relevant antibodies.
Association of HIV-specific parameters (CD4þ T-cell
counts, viral loads and duration of infection) with
binding and neutralizing antibody titers identified
CD4þ T-cell counts as positive predictor for homo-
subtypic and as negative predictor for heterosubtypic
antibodies. Thus, in HIV-infected individuals, CD4þ
T cells appear beneficial for antibody responses to
homosubtypic viruses but disadvantageous for hetero-
subtypic antibody responses.
Previous studies either identified the number of CD4þ
T-cells as a direct determinant of the antibody response
to influenza vaccination [18,20], or could not show
correlations between influenza serum antibody titers and
CD4þ T-cell counts in HIV-infected subjects [8]. Besides
lowCD4þT-cell numbers, high viral loads and prolonged
duration of untreated disease progression favored the
generation of heterosubtypic antibodies. Thus, HIV-
induced damage to the immune system seems to favor the
generation of heterosubtypic antibodies. One might
speculate that a decimation of overrepresented homo-
subtypic memory B cells allows for less abundant
heterosubtypic B cells to expand without heavy
competition by abundant heterosubtypic B cells.
In contrast, binding and neutralizing antibody titers to
both heterosubtypic and homosubtypic viruses increased
with ART treatment duration. This may be explained by
a strong association of the duration of ART treatment and
the number of vaccinations. Although all other HIV
parameters showed contrary results for heterosubtypes
and homosubtypes, treatment duration equally improved
titers to both homosubtypic and heterosubtypic viruses in
response to vaccination.
Although the overall picture from these observations is
intriguing and logical, it has to be mentioned that the
individual significance levels for the HIV parameter-
related analyses are not very strong, and also the pattern of
significances could be more consistent.
Nonetheless, our results clearly support the importance of
vaccination of HIV-infected individuals against influenza
viruses. To promote an immune response in HIV-positive
individuals that also produces antibodies to heterosub-
typic avian strains, vaccine designs need to be improved to
induce antibodies directed against conserved epitopes be
enclosed in both human homosubtypic and hetero-
subtypic strains and in avian heterosubtypic strains.
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